Hua Jian and Renhe Launch OTC Drug RWA Platform to Modernize Supply Chains
Concord Medical (HKEX: 0370) has disclosed that its affiliate Hua Jian Medical is partnering with Renhe International, a wholly-owned arm of Renhe Pharmaceutical, to build a new real-world asset (RWA) platform for over-the-counter (OTC) drugs.
The venture is being described as the first vertical RWA system dedicated to OTC pharmaceuticals, with the aim of streamlining supply chains and improving transparency in China’s rapidly growing OTC market.
Tokenizing OTC Drugs for Secure, Real-Time Trading
The project is still in development, but the companies said it will tokenize OTC pharmaceutical assets, enabling secure, traceable, and real-time transactions between manufacturers, distributors, and retailers.
By moving drug inventories and transactions onto blockchain rails, the partners expect to cut inefficiencies, lower costs, and improve compliance with regulatory standards, while giving market participants more confidence in product authenticity.
Related: RWA Sector Hits Record $25B Value, Led by Private Credit and U.S. Treasuries
Renhe’s Role in Tech Infrastructure
Renhe International brings its background in digital transformation and blockchain adoption to the initiative. Its role is focused on developing a scalable and secure technology infrastructure to support the platform.
Executives noted that the effort reflects Hua Jian’s broader strategy to combine healthcare and technology, particularly in the distribution layer where bottlenecks and fraud risks often arise.
Why China’s OTC Market Matters
China’s OTC market has been expanding in both urban and rural areas as self-care and preventive medicine gain traction. Industry data cited by the companies suggests this segment of healthcare could become a major growth driver in the coming years.
By digitizing and tokenizing OTC drug flows, Hua Jian and Renhe aim to accelerate distribution, improve responsiveness to demand shifts, and reduce friction in retail delivery.
Industry Implications
Analysts say this partnership could become a model for integrating RWAs into pharmaceutical supply chains, a sector traditionally slow to adapt to digital innovation.
If successful, the framework may influence how OTC drugs are traded not only in China but also across international healthcare markets.
Related: RWA Crypto Sector Emerges as Day’s Top Performer with 6.9% Gain
Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.